BiomX (PHGE) Stock Price, News & Analysis

Company Overview

BiomX Inc. is a clinical-stage biotechnology company developing precision therapies that target harmful bacteria while seeking to preserve beneficial microorganisms. The company’s platform uses naturally occurring bacteriophages, or viruses that selectively infect and destroy specific bacteria, to address diseases associated with the microbiome.

BiomX has focused its research and development programs on conditions including cystic fibrosis and inflammatory bowel disease. Its pipeline has included BX004, an inhaled phage therapy designed to target Pseudomonas aeruginosa in the lungs of people with cystic fibrosis, and BX211, an investigational therapy intended to target disease-associated bacteria in the gastrointestinal tract.

Founded in Israel and with roots connected to research conducted at the Weizmann Institute of Science, BiomX has operated as a publicly traded biotechnology company since completing a business combination in 2019. The company has conducted development activities through operations in Israel and the United States. As a clinical-stage company, BiomX’s programs remain subject to clinical testing and regulatory review, and their safety and effectiveness have not been established for commercial use.

Key Stats

• Today's Range: $1.65 to $2.16
• 50-Day Range: $1.42 to $1.85
• 52-Week Range: $1.19 to $122.93
• Volume: 3.33 million shs
• Average Volume: 364,372 shs
• Market Capitalization: $4.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $260.00
• Consensus Rating: Hold

BiomX Stock Analysis - MarketRank™

BiomX scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

BiomX has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

BiomX has a consensus price target of $260.00, representing about 13,954.1% upside from its current price of $1.85.

Amount of Analyst Coverage

BiomX has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for BiomX are expected to decrease in the coming year, from ($58.50) to ($60.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BiomX is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BiomX is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PHGE.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BiomX does not currently pay a dividend.

Dividend Growth

BiomX does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for BiomX this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BiomX insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.23% of the stock of BiomX is held by insiders.

Percentage Held by Institutions

40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/19/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:PHGE
• Previous Symbol: NYSEMKT:PHGE
• CIK: 1739174
• Web: www.biomx.com
• Phone: 972-7-2394-2377
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BiomX: $260.00
• High Price Target: $260.00
• Low Price Target: $260.00
• Potential Upside/Downside: +13,954.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.20 million
• Net Margins: N/A
• Pretax Margin: -13,700.30%
• Return on Equity: N/A
• Return on Assets: -165.38%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 0.24
• Quick Ratio: 0.24

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($124.99) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 2,670,000
• Free Float: 2,666,000
• Market Cap: $4.94 million
• Optionable: N/A
• Beta: 1.33